company background image
SBFM

Sunshine Biopharma NasdaqCM:SBFM Stock Report

Last Price

US$1.24

Market Cap

US$23.4m

7D

-2.4%

1Y

-95.2%

Updated

12 Aug, 2022

Data

Company Financials
SBFM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SBFM Stock Overview

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs.

Sunshine Biopharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sunshine Biopharma
Historical stock prices
Current Share PriceUS$1.24
52 Week HighUS$29.80
52 Week LowUS$1.03
Beta-1.74
1 Month Change8.77%
3 Month Change-38.00%
1 Year Change-95.19%
3 Year Change-86.52%
5 Year Change-99.82%
Change since IPO-100.00%

Recent News & Updates

Aug 08
We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Aug 04

Sunshine Biopharma reports 1H results

Sunshine Biopharma press release (NASDAQ:SBFM): 1H Revenue of $0.27M. The Company had a net loss of $1,775,106 in the first half of 2022, compared to a net loss of $9,064,180 in the first half of 2021.

Apr 17

Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs

Sunshine Biopharma is developing novel Topoisomerase II inhibiting cancer therapies and PLpro inhibiting antiviral drugs. The Company has a strong IP backing, although much of it is tied in with the CEO. The Company recently raised $13.6 million in net proceeds from a public offering following a 200:1 reverse split, and a private placement. Note: we do not recommend stocks with such low market caps however attractive they may otherwise sound.

Shareholder Returns

SBFMUS BiotechsUS Market
7D-2.4%1.2%3.2%
1Y-95.2%-21.7%-10.1%

Return vs Industry: SBFM underperformed the US Biotechs industry which returned -23% over the past year.

Return vs Market: SBFM underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is SBFM's price volatile compared to industry and market?
SBFM volatility
SBFM Average Weekly Movement14.1%
Biotechs Industry Average Movement12.5%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: SBFM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: SBFM's weekly volatility has decreased from 38% to 14% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a3Steve Slilatyhttps://www.sunshinebiopharma.com

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements.

Sunshine Biopharma, Inc. Fundamentals Summary

How do Sunshine Biopharma's earnings and revenue compare to its market cap?
SBFM fundamental statistics
Market CapUS$23.42m
Earnings (TTM)-US$5.15m
Revenue (TTM)US$408.45k

57.4x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SBFM income statement (TTM)
RevenueUS$408.45k
Cost of RevenueUS$215.32k
Gross ProfitUS$193.12k
Other ExpensesUS$5.34m
Earnings-US$5.15m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.27
Gross Margin47.28%
Net Profit Margin-1,260.23%
Debt/Equity Ratio0.0%

How did SBFM perform over the long term?

See historical performance and comparison